LIVER DISEASES THERAPEUTICS MARKET ANALYSIS

Market Challenges And Opportunities

Global Liver Diseases Therapeutics Market : Key Trends

Awareness programs by government and non-profit organizations can drive market growth. On March 30, 2022, Global Liver Institute, U.S. based nonprofit organization, launched its ‘Liver health is Public health’ initiative. It is a multi-year awareness program that will address ongoing challenges in the diagnosis and treatment of liver diseases, and shift the conversation on liver health. It will develop workgroups and assess the state of liver health globally, develop education resources for diverse audiences, and empower a global cohort of liver health advocates.

Introduction of newer therapies by researchers can drive market growth. On January 24, 2023, the Medical University of Vienna, Australia-based public research university, announced that it has developed a new liver disease treatment method for alcohol-related liver disease treatment. The researchers collaborated with a team from the University of California, U.S.-based research university. Together they identified a previously unknown function of the polymeric immunoglobulin receptor (pIgR) in alcohol-related liver disease. Preclinical studies have shown that pIgR-mediated secretion of certain antibodies (immunoglobulin A or IgA) in the intestines is vital in protecting the liver against alcohol-related damage. Hence, enhancing pIgR in the liver or increasing the IgA levels in the intestine could be a promising starting point for novel treatment options for alcohol-related liver disease.

Global Liver Diseases Therapeutics Market: Restraint

Availability of alternative methods to liver disease therapeutics

The treatment of chronic liver diseases lasts for a longer duration which makes it expensive  and reduces patient adherence to treatment. The availability of alternative methods like organ transplantation and liver resection can limit the growth of the global liver diseases therapeutics market. For instance, according to an article published by the World Journal of Transplantation on March 31, 2020, different treatments like Xeno-organ transplantation, scaffold-based transplantation, and cell transplantation can be employed for the treatment of liver failure. Cell transplantation can be achieved using hepatocytes, umbilical cord-derived mesenchymal stem cells (MSCs), bone marrow-derived MSCs, and hematopoietic stem cells.  

This counterbalance this restrain, a more effective treatment should be introduced with vigorous research and development activity that can minimize the need for organ transplantation.

Withdrawal of clinical trials

Many clinical trials are being conducted to ensure that the treatment is safe and effective. However, due to uninspiring results, the clinical trials are withdrawn from the market which can limit the growth of the global liver diseases therapeutics market during the forecast period. For instance, on October 25, 2022, Novartis AG, a Switzerland-based pharmaceutical company, announced that it has stopped work on the use of iscalimab for liver transplant program after the phase 2 trial delivered lackluster results. Phase 2 trial found the anti-CD40 antibody has a less favorable risk-benefit profile than tacrolimus, which Astellas Pharma sells as Prograf, in liver transplant patients

This can be counterbalanced by carrying out more dedicated research on newer drug therapies that can provide better results.